|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1QTNF3 |
Gene summary for C1QTNF3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1QTNF3 | Gene ID | 114899 |
| Gene name | C1q and TNF related 3 | |
| Gene Alias | C1ATNF3 | |
| Cytomap | 5p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q9BXJ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114899 | C1QTNF3 | HCC1 | Human | Liver | HCC | 8.45e-13 | 6.03e+00 | 0.5336 |
| 114899 | C1QTNF3 | S014 | Human | Liver | HCC | 3.84e-27 | 2.60e+00 | 0.2254 |
| 114899 | C1QTNF3 | S015 | Human | Liver | HCC | 3.20e-04 | 1.91e+00 | 0.2375 |
| 114899 | C1QTNF3 | S016 | Human | Liver | HCC | 8.90e-37 | 3.23e+00 | 0.2243 |
| 114899 | C1QTNF3 | C08 | Human | Oral cavity | OSCC | 2.53e-03 | 3.86e-03 | 0.1919 |
| 114899 | C1QTNF3 | ATC13 | Human | Thyroid | ATC | 5.13e-86 | 2.85e+00 | 0.34 |
| 114899 | C1QTNF3 | ATC5 | Human | Thyroid | ATC | 6.56e-90 | 3.03e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190495122 | Liver | HCC | positive regulation of establishment of protein localization | 207/7958 | 319/18723 | 3.95e-16 | 3.29e-14 | 207 |
| GO:005122222 | Liver | HCC | positive regulation of protein transport | 194/7958 | 303/18723 | 2.41e-14 | 1.56e-12 | 194 |
| GO:000599621 | Liver | HCC | monosaccharide metabolic process | 167/7958 | 257/18723 | 2.31e-13 | 1.25e-11 | 167 |
| GO:001931821 | Liver | HCC | hexose metabolic process | 155/7958 | 237/18723 | 7.63e-13 | 3.90e-11 | 155 |
| GO:000600621 | Liver | HCC | glucose metabolic process | 128/7958 | 196/18723 | 8.60e-11 | 3.06e-09 | 128 |
| GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
| GO:00463642 | Liver | HCC | monosaccharide biosynthetic process | 58/7958 | 82/18723 | 2.08e-07 | 3.75e-06 | 58 |
| GO:000610921 | Liver | HCC | regulation of carbohydrate metabolic process | 109/7958 | 178/18723 | 3.36e-07 | 5.78e-06 | 109 |
| GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
| GO:00193192 | Liver | HCC | hexose biosynthetic process | 54/7958 | 78/18723 | 1.61e-06 | 2.27e-05 | 54 |
| GO:00109062 | Liver | HCC | regulation of glucose metabolic process | 76/7958 | 119/18723 | 2.03e-06 | 2.79e-05 | 76 |
| GO:00060942 | Liver | HCC | gluconeogenesis | 52/7958 | 75/18723 | 2.34e-06 | 3.14e-05 | 52 |
| GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
| GO:004426221 | Liver | HCC | cellular carbohydrate metabolic process | 153/7958 | 283/18723 | 5.27e-05 | 5.00e-04 | 153 |
| GO:00160512 | Liver | HCC | carbohydrate biosynthetic process | 113/7958 | 202/18723 | 7.64e-05 | 6.83e-04 | 113 |
| GO:00106772 | Liver | HCC | negative regulation of cellular carbohydrate metabolic process | 28/7958 | 42/18723 | 1.35e-03 | 7.26e-03 | 28 |
| GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
| GO:00061111 | Liver | HCC | regulation of gluconeogenesis | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
| GO:00459122 | Liver | HCC | negative regulation of carbohydrate metabolic process | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
| GO:00432551 | Liver | HCC | regulation of carbohydrate biosynthetic process | 56/7958 | 97/18723 | 1.75e-03 | 9.11e-03 | 56 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1QTNF3 | SNV | Missense_Mutation | rs551906960 | c.881N>A | p.Arg294Gln | p.R294Q | Q9BXJ4 | protein_coding | tolerated(1) | possibly_damaging(0.521) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C1QTNF3 | SNV | Missense_Mutation | c.511N>T | p.Arg171Trp | p.R171W | Q9BXJ4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| C1QTNF3 | SNV | Missense_Mutation | c.703N>T | p.Val235Leu | p.V235L | Q9BXJ4 | protein_coding | tolerated(0.19) | benign(0.088) | TCGA-E9-A1QZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1QTNF3 | insertion | Nonsense_Mutation | novel | c.511_512insTTCATCTTCTTTCTTGTAGCTGAATGTACCAAAGTATATTTAAT | p.Arg171LeufsTer8 | p.R171Lfs*8 | Q9BXJ4 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| C1QTNF3 | SNV | Missense_Mutation | c.511C>T | p.Arg171Trp | p.R171W | Q9BXJ4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C1QTNF3 | SNV | Missense_Mutation | rs142993560 | c.395C>T | p.Pro132Leu | p.P132L | Q9BXJ4 | protein_coding | tolerated(0.06) | benign(0.103) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C1QTNF3 | SNV | Missense_Mutation | c.694N>A | p.Val232Ile | p.V232I | Q9BXJ4 | protein_coding | tolerated(0.33) | probably_damaging(0.953) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| C1QTNF3 | SNV | Missense_Mutation | c.35T>C | p.Leu12Pro | p.L12P | Q9BXJ4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C1QTNF3 | SNV | Missense_Mutation | c.11N>T | p.Arg4Met | p.R4M | Q9BXJ4 | protein_coding | deleterious_low_confidence(0) | benign(0.058) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| C1QTNF3 | SNV | Missense_Mutation | c.550G>A | p.Gly184Arg | p.G184R | Q9BXJ4 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |